Side effects were similar in kids as they were adults. No one in the trial developed severe side effects, including myocarditis or pericarditis.
And for older kids: The company also announced that it had begun submitting data to Food and Drug Administration to authorize its vaccine for kids 6 to 11 years old, and that it was submitting additional data for those 12 to 17.
Background: In fourth quarter earnings calls earlier this year, the company said it would be decreasing the dose size for the youngest children.
What’s next: The company plans to ask the FDA to authorize the vaccine for this age group in the coming weeks. It is also planning to study booster doses for kids.